- Home » News and Events
NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
Nov 5, 2019
Catalent today announced it will present at the upcoming World Orphan Drug Congress Europe, being held at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019.
Catalent Biologics Launches GPEx® Boost Cell Line Expression Technology to Improve Titers and Cell-Specific Productivity
Nov 4, 2019
Catalent, today announced the launch of its next-generation cell line development technology, GPEx® Boost.
Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
Sep 12, 2019
Catalent, today announced that professor David Schaffer has been appointed to the advisory board of the company’s biologics business.
Flexible Filling And Adoption Of ‘Ready-to-Use’ Technologies To Be Discussed By Catalent Biologics At The Pharma Forum
Sep 10, 2019
Catalent today announced that Alex Haig, Senior Director, Engineering will present at the Pharma Forum, to be held at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18 – 19, 2019.
Novavax and Catalent Announce Closing of Strategic Partnership
Jul 31, 2019
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector development and manufacturing partner for gene therapies, today announced the closing of their previously announced arrangement.
Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
Jul 16, 2019
Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).
Catalent’s Partner, Passage Bio, Announces New Dedicated Gene Therapy Manufacturing Suite
Jul 10, 2019
The dedicated cGMP suite is to be built under strategic partnership with Paragon Gene Therapy to support future clinical and commercial production for Passage Bio’s AAV-delivered gene therapies
Catalent’s Partner, Amicus, Announces It Has Entered Into A Strategic Partnership With Catalent For Gene Therapy Development And Manufacturing
Jul 2, 2019
The agreement supports clinical and commercial supply needs for Pompe and other lysosomal disease gene therapy programs
The Use of Continuous Chromatography in Effective Process Design to be Presented by Catalent Biologics Expert at PREP Symposium
Jul 2, 2019
Catalent today announced that Ben Kester, Manager and Senior Scientist, Purification Development, Catalent Biologics, will present at the upcoming 32nd International Symposium on Preparative and Process Chromatography (PREP Symposium).
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.